Shandong Xinhua Pharmaceutical Co. (00719) has announced that the company recently received the "Drug Supplementary Application Approval Notice" for Nimodipine Tablets issued by the National Medical Products Administration, confirming that the product has passed the generic drug quality and efficacy consistency evaluation.
In July 2025, Shandong Xinhua Pharmaceutical submitted the consistency evaluation application materials for Nimodipine Tablets to the Center for Drug Evaluation (CDE) of the National Medical Products Administration, which were accepted. In October 2026, the "Drug Supplementary Application Approval Notice" was obtained, with the review conclusion stating that upon examination, the product has passed the generic drug quality and efficacy consistency evaluation.
This product, used as continued treatment following pre-treatment with Nimodipine Injection, can prevent and treat ischemic neurological damage caused by cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
The product can also be used to treat senile cerebral dysfunction, such as memory decline, disorientation and attention disorders, and mood swings. Before treatment, it should be determined that these symptoms are not caused by underlying diseases requiring special treatment.
Comments